http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Exelixis (EXEL), Arcus Biosciences (RCUS) Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
-
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
-
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
-
Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
-
Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences
-
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
-
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
-
Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences’ Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer
-
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
-
Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update
-
Arcus Biosciences to Participate in the Barclays Global Healthcare Conference
-
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Gilead (GILD) and Arcus (RCUS) Report Strong Interim Results of ARC-7 Study
-
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
-
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Gilead (GILD) and Arcus Biosciences (RCUS) Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
-
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
-
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences (RCUS) Appoints Dimitry Nuyten as Chief Medical Officer
-
Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer
-
Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update
-
Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study
-
Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Pre-Open Stock Movers 04/05: (RCUS) (TWTR) (EZPW) Higher; (XPOF) (CVNA) (FSLR) Lower (more...)

